Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2019 07:00 ET | Source: Arcturus Therapeutics Holdings Ltd

Arcturus to Report Corporate Overview and Financial Results on August 15

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and...
August 02, 2019 14:00 ET | Source: Arcturus Therapeutics Holdings Ltd

Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock

SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of...
August 01, 2019 12:30 ET | Source: Arcturus Therapeutics Holdings Ltd

Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock

SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of...
August 01, 2019 12:10 ET | Source: Arcturus Therapeutics Holdings Ltd

Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients

SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company, today announced that the Cystic Fibrosis Foundation (CF...
July 10, 2019 09:00 ET | Source: Arcturus Therapeutics Holdings Ltd

Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference

SAN DIEGO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and...
June 27, 2019 16:01 ET | Source: Arcturus Therapeutics Holdings Ltd

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO, June 27, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics...
June 13, 2019 07:00 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation

SAN DIEGO, June 13, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and...
May 20, 2019 11:02 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics

SAN DIEGO, May 20, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and...
May 13, 2019 07:00 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update

SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of...
March 18, 2019 07:00 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results

SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of...